BriaCell Therapeutics Corp. announced the approval of a share consolidation
The consolidation aims to comply with Nasdaq listing requirements
Post-consolidation shares to trade under symbols BCT and BCTX
Share Consolidation Approval
Board of directors approved the consolidation of common shares.
Effective Date
Expected to become effective on August 25, 2025.
Trading Symbols
Post-consolidation shares to trade under symbols BCT and BCTX.
- Shareholders to receive instructions for exchange of common shares
- No fractional common shares to be issued in connection with the consolidation
Shareholders should stay informed about the consolidation process and follow instructions provided by the company.